vedolizumab,infliximab
takeda,janssen
['ibd', 'ease data', 'infliximab', ' aa ', 'inflammatory,bowel', 'vedo', 'crohn']
#ecco2023 comunicaci n p ster geteccu: real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. results from the eneida registry. m. iborra 
Twitter oficial del Grupo Español de Trabajo en #EnfermedaddeCrohn y Colitis Ulcerosa (GETECCU). Contenido orientado a profesionales sanitarios 👨‍⚕️👩‍⚕️